Laurus Labs schedules investor meets on May 27, June 4
Laurus Labs announced it will participate in analyst and institutional investor meetings in Mumbai on May 27 and June 4, 2026. The company stated no unpublished price sensitive information will be shared during these interactions.

*this image is generated using AI for illustrative purposes only.
Laurus Labs has intimated the stock exchanges regarding its schedule of analyst and institutional investor meetings. The company will participate in these conferences pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The meetings are scheduled to take place in Mumbai. The company clarified that no unpublished price sensitive information would be shared during these interactions.
Schedule of Meetings
The following table outlines the dates, events, and types of interactions planned for the upcoming investor conferences:
| Date | Analyst / Investors / Event | Place | Type of Interaction |
|---|---|---|---|
| May 27, 2026 | 360 ONE Capital (B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 | Mumbai | In-Person Meeting |
| June 04, 2026 | Citi 2026 India Conference | Mumbai | In-Person Meeting |
The company noted that the dates of these meetings are subject to change due to exigencies on the part of investors or the company. The intimation was signed by G. Venkateswar Reddy, Company Secretary & Compliance Officer.
Historical Stock Returns for Laurus Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.30% | +3.51% | +23.39% | +40.55% | +130.89% | +166.41% |
What strategic updates or pipeline developments might Laurus Labs highlight to institutional investors at these conferences to boost market confidence?
How could increased institutional investor engagement at these conferences influence Laurus Labs' stock performance and foreign institutional ownership in the near term?
Will Laurus Labs use these investor meetings to address concerns about its recent financial performance or provide guidance on its CDMO and ARV business recovery trajectory?


































